| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
KalVista Pharmaceuticals Inc (NASDAQ: KALV)
KALV Technical Analysis
4
| As on 9th Jun 2023 KALV STOCK Price closed @ 9.91 and we RECOMMEND Sell for LONG-TERM with Stoploss of 11.91 & Strong Sell for SHORT-TERM with Stoploss of 13.82 we also expect STOCK to react on Following IMPORTANT LEVELS. |
KALVSTOCK Price
| Open | 10.04 | Change | Price | % |
| High | 10.04 | 1 Day | -0.08 | -0.80 |
| Low | 9.79 | 1 Week | 0.43 | 4.54 |
| Close | 9.91 | 1 Month | 1.86 | 23.11 |
| Volume | 239981 | 1 Year | -3.29 | -24.92 |
| 52 Week High 16.97 | 52 Week Low 4.20 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| KALV Daily Charts |
KALV Intraday Charts |
Whats New @ Bazaartrend |
KALV Free Analysis |
|
|
KALV Important Levels Intraday
| RESISTANCE | 10.39 |
| RESISTANCE | 10.24 |
| RESISTANCE | 10.14 |
| RESISTANCE | 10.05 |
| SUPPORT | 9.77 |
| SUPPORT | 9.68 |
| SUPPORT | 9.58 |
| SUPPORT | 9.43 |
KALV Forecast April 2024
| 4th UP Forecast | 21.11 |
| 3rd UP Forecast | 17.52 |
| 2nd UP Forecast | 15.3 |
| 1st UP Forecast | 13.08 |
| 1st DOWN Forecast | 6.74 |
| 2nd DOWN Forecast | 4.52 |
| 3rd DOWN Forecast | 2.3 |
| 4th DOWN Forecast | -1.29 |
KALV Weekly Forecast
| 4th UP Forecast | 12.57 |
| 3rd UP Forecast | 11.72 |
| 2nd UP Forecast | 11.19 |
| 1st UP Forecast | 10.66 |
| 1st DOWN Forecast | 9.16 |
| 2nd DOWN Forecast | 8.63 |
| 3rd DOWN Forecast | 8.10 |
| 4th DOWN Forecast | 7.25 |
KALV Forecast2024
| 4th UP Forecast | 35.38 |
| 3rd UP Forecast | 27.21 |
| 2nd UP Forecast | 22.16 |
| 1st UP Forecast | 17.11 |
| 1st DOWN Forecast | 2.71 |
| 2nd DOWN Forecast | -2.34 |
| 3rd DOWN Forecast | -7.39 |
| 4th DOWN Forecast | -15.56 |
KalVista Pharmaceuticals Inc ( NASDAQ USA Symbol : KALV )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
KALV Business Profile
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service